INDEX S.NO 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 CONTENT COMPANY OVERVIEW PRODUCT OVERVIEW FACTORS AFFECTING SUPPLY FACTORS AFFECTING DEMAND MARKET SURVEY RESPONSE OF CONSUMER OBSERVVATION DEMAND SCHEDULE TYPE OF COMPETITION FORM OF MARKET STRUCTURE SHORT RUN EQUILIBRIUM LONG RUN EQUILIBRIUM LEVEL OF BARRIERS AFFECT ON PRICE STRATEGY FINANCIAL STATEMENT PAGE NO 3 6 8 10 12 13 14 15 16 17 18 19 20 22 23

16 17

CSR BIBLIOGRAPHY

29 34

Company Overview

Date of Establishment Revenue Market Cap BnCorporate Address

1983 580.952 ( USD in Millions ) 161393.894597 ( Rs. in Millions ) 159 C S T Road,KalinaSantacruz (East), Mumbai-400098, Maharashtra www.lupinworld.com Chairperson - DeshBandhu Gupta MD - Kamal K Sharma Directors - D K Contractor, DeshBandhu Gupta, K U Mada, K V Kamath, K V Kamoth, Kamal K Sharma, M D Gupta, Marc Desaedeleer, Nilesh Gupta,

Management Details

. Ankleshwar. Sunil Nair. Richard Zahn. Vinita Gupta Business operationBackground Pharmaceuticals & Drugs Lupin is a transnational company engaged in development of APIs. Mandideep. Tarapur. generic and branded formulations. R V Satam. Vijay Kelkar. It is the largest manufacturer of Tuberculosis drugs in the world. Indore. It has onshore and offshore presence of its products in 70 countries.R A Shah. Jammu. Its manufacturing unit is located in Goa.

Key excutive S.No 1 3 2 4 5 6 7 8 9 10 11 12 13 14 15 Name DeshBandhu Gupta Kamal K Sharma R V Satam D K Contractor Vinita Gupta K U Mada R A Shah M D Gupta Nilesh Gupta Vijay Kelkar K V Kamoth Richard Zahn K V Kamath Vijay Kelkar Richard Zahn Designation Chairman Managing Director Company Secretary Director Director Director Director Executive Director Executive Director Additional Director Additional Director Additional Director Independent Director Independent Director Independent Director .

INTRODUCTION OF LUPIN PHARMA About Lupin Headquartered in Mumbai. Pediatrics. The Company’s foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals. Lupin Pharmaceuticals. wholly owned subsidiary of Lupin Ltd.145 million (US$ 851 million) and Rs. Today. CNS. Diabetology. The company is also the fastest growing. top 5 pharmaceutical players in India (ORG IMS . Lupin Pharmaceuticals.S. affordable generic and branded formulations and APIs for the developed and developing markets of the world. India. The Company’s R&D endeavors have resulted in significant progress in its NCE program. Anti-Infectives and NSAIDs therapy segments. is the U.S (ranked 8th by prescriptions & growing at 50 %) and Japan (ranked 7th and growing at 23%). Headquartered in Baltimore. Asthma. Inc.lupinpharmaceuticals. Lupin has the unique distinction of being the fastest growing top 10 Generics players in the two largest pharmaceutical markets of the world – The U. .March 2009) and the fastest growing Generic player in South Africa (ranked 6th and growing at 36 % YoY .IMS) For the financial year ended March 2009.lupinworld. Inc. 5015 million (US$ 109 million) respectively. visithttp://www. Our Drugs and products reach over 70 countries in the world. Please visit http://www. GI.com. The Company today has significant market share in key markets in the Cardiovasculars (prils and statins).com for more information about Lupin Ltd.39. Lupin's Consolidated Revenues and Profit after Tax were Rs. For more information. affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. Maryland. is dedicated to delivering high-quality. Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality. not to mention global leadership positions in the Anti-TB and Cephalosporins.

162mn Anti-TB market. As market leaders in this space. Lupin has embarked on an effort which would redefine the treatment guidelines based on conditions existing in India under the aegis of RIETT-Redefining Indian Expertise Based Tuberculosis Treatment.Lupin Pharma The Company’s concerted focus on the semi-acute therapy is the crux of the Lupin division.3. Key Products : LupinPharma . Lupin commands 48% of the market share. In a Rs. which has enabled the Company to attain market leadership in the Anti-TB segment of IPM.

54 29.67 2038.86 1546.91 2271/1086 .89 320119.75 1289.16 7.05 316.Product R-Cinex AKT Akurit R-CIN G-CIN Combutol Pyzina Therapeutic segment Anti-TB Anti-TB Anti-TB Anti-TB Gemifloxacin Ethambutol& Comb. Glaxosmithkline Phar 38615.59 1. (Rs.30 32.99 23.Million ) Current Price Change (%) P/E Ratio Market Cap.90 0.Million) 52-Week High/Low Sun Pharma Cipla Dr Reddy's Ranbaxy Labs. Pyrazinamide Plain Product Rank in the relevant segment 1 1 1 1 1 1 2 Company Sales(Rs.03 173149.50 49606.03 0.76 221305.31 363/211 1335/598 538/217 18707.09 1846/1070 254164.00 47802.06 -1.90 422.00 -0.49 26.65 175208.00 41589.

92 9744.92 70546.67 45025.28 163/42 351.60 16985.22 0.Lupin Cadila Healthcare Piramal Healthcare Divi'S Lab GlenmarkPharma Biocon Jubilant Life AurobindoPharma TorrentPh Aventis Pharma Matrix Laboratories Pfizer Ipca Laboratories Ster.00 500.60 11905.60 612.38 19794.90 1873.75 91238.19 16.84 104997.47 105/57 .09 0.32 8310.00 0.15 20732.94 1844/755 838/188 600/250 728/452 304/199 311/164 373/155 990/326 555/164 42675.30 17.84 1.66 1.00 1.84 227/165 1125/711 304/85 146/90 3965.05 3.06 841.16 161393.89 121845.00 244.83 129.06 15021.90 22.27 1.87 24.05 112.00 271.41 39.92 27796.79 22.55 344.79 2.34 27948.00 19251.84 -0.69 34.36 56740.74 1968/1030 32729.00 209.45 286.00 23162.81 24.30 11848.42 3.62 48392.89 18.00 1.50 1109/570 2620.40 11783.21 23.53 31288.15 0.60 8545.04 44.60 538.14 -1.71 27.08 0.12 2.59 9123.Biot AstrazenecaPharm a Fresenius KabiOncol SunPhaAdv 28985.00 0.65 721.00 882.85 14.37 24285.01 21.42 93.00 53659.81 1815.75 30899.34 4.44 12956.35 1050.16 53.78 10.

03 2.40 1072.40 11977.77 16718.10 368.60 16.00 91.69 11.61 6200.00 28.41 14.00 403.94 9604.10 11914.82 10416.95 351.70 173.19 2.14 12257.59 29.40 121.85 2863.75 0.15 221.19 13165.40 7279.16 1.70 6.86 0.37 14357.78 15000.99 17854.25 37.85 81.27 -2.43 7734.00 1.67 15038.05 400.35 611.15 14.28 1.96 13.68 6767.22 0.95 297.28 6181.62 7694.00 140.72 1.79 4919.14 16.95 635.42 0.57 6568.84 11319.89 11.75 6608.40 47.34 0.95 3.78 8488.25 29.60 5763.Novartis DishmanPharma Wyeth FDC Strides Arcolab Abbott India Unichem Lab Wockhardt Solvay Pharma PlethicoPharma Panacea Biotec Merck Orchid Chemicals Nectar Lifesciences JB Chem&Pharma Elder Pharma Shilpa Medicare Alembic Indoco Remedies 5994.57 19.27 1.88 13.26 4721.55 10940.12 15.32 21.81 0.80 4158.91 2417.42 7945.67 3.62 0.90 785.22 1359.61 6455.17 4731.10 2519.00 10.47 1.31 5.28 6753.24 17630.60 633/385 275/136 850/500 96/37 371/98 1210/415 453/189 201/107 3600/650 405/151 248/100 687/371 239/78 44/15 96/37 408/218 363/64 56/35 442/148 .85 3506.50 346.69 18923.50 15587.83 10.95 -3.29 1.

33 4.43 2214.90 183.63 4.00 3.90 3821.60 193.14 3472.87 3.95 3540.83 3065.78 4465.57 3.00 107.86 2427.50 990.01 0.25 266.35 1.32 2194.00 24.50 342.57 8.75 164/35 12800/251 3 72/18 435/101 196/75 216/82 132/33 312/182 .30 130.44 2873.66 22.46 4708.24 3864.40 -2.14 -0.15 7.59 2.00 112.78 184/71 51/15 255/57 139/93 1150/436 12/7 251/100 1400.56 3.00 58.92 1329.40 2758.73 2725.08 3.85 185.67 4290.50 4.35 3.23 1947.99 0.04 9653.56 2260.11 28.03 1.47 7229.80 9.45 -2.72 10.25 0.00 42.26 6.50 0.00 1641.43 2640.78 3204.75 37/18 21.65 2.62 877.40 2.11 2.00 3163.11 26.NatcoPharma Bliss GVS Parenteral Drugs Zenotech Lab.94 139.60 152/50 1060.25 0.65 3801.66 3384.74 60.21 162.00 172.82 3821.46 14.66 3704. Fulford India Morepen Labs Ankur Drugs Suven Life Sciences Piramal Life Science Sequent Scientific Zandu Realty Shasun Chemicals TTK Healthcare Surya Pharma Alchemist Twilight Litaka Phar Venus Remedies 2696.25 13.60 29.09 45.79 2252.34 2196.

32 10.50 613.26 2.42 1854.17 707.95 4.03 0.18 1537.45 1277.89 1429.91 115.59 0.92 1995.42 5870.47 1.62 1085.58 7.80 96.41 37/9 37/16 96/44 465/172 .85 0.29 11.08 8.84 2088.00 2445.68 5.30 245.81 1811.00 71.23 3.41 2.74 906.28 3765.97 1144.99 2.14 2.85 4.32 12.Ajanta Pharma Themis Medicare Granules India Amrutanjan Health IndSwiLab Phaarmasia SMS Pharma MarksansPharma Vivimed Labs Jupiter Bioscience Aarti Drugs Anu's Labs Kilitch Drugs Sharon BioMedicine Kopran IndSwiLtd Wanbury AnuhPharma 3194.37 144/42 1186.00 66.58 1510.67 10.80 1727.61 1051.00 2.12 183.94 14.05 1.77 1998.95 111.98 2538.43 3.02 1028.00 167.80 1912.49 1563.22 1642.10 29.40 1900.75 81.25 5.35 1.96 4.55 1672.60 3.60 5834.50 72.75 3.45 377.31 7.77 0.62 7.90 5.66 3.00 2.62 1311.23 -4.35 156.88 1205.09 1290.03 1597.00 7.30 1182.29 1318.50 253.90 100.30 1514.97 212/73 301/60 115/52 1345/324 80/34 344/253 190/109 8/4 175/65 105/52 128/48 27/5 157/59 4197.03 1.95 112.13 32.

60 2056.65 457.22 1885.60 2.20 -4.86 29.89 92/26 71.19 34.RPG Life Sciences Bharat Immunological Ambal Sarabhai Hester Biosciences Albert David Syncom Healthcare BafnaPharma Adinath Bio-Lab Lyka Labs DIL JagsonpalPharma Neuland Lab.00 4.00 21.05 39.20 94.08 18.23 426.50 124.49 0.30 10.02 0.68 1361.10 1. HiranOrgochem Kerala Ayurveda Gufic Biosciences Arvind Remedies Smruthi Organics AhlconParenterals 1392.10 301.95 9.67 179.88 729.43 70.38 0.54 378.13 1.73 1.30 -0.45 7.19 0.50 5.19 765.80 5.29 3.76 2178.20 43.75 17.00 3.05 6.53 2.00 36.12 9.80 17.70 0.85 515.25 675.58 478.61 17/10 156/76 143/62 162/39 45/19 21/3 41/17 309/146 27/11 160/92 13/4 66/30 11/4 3/1 132/38 58/22 .10 521.03 5.87 494.13 5.00 0.25 263.73 105.99 218.57 713.14 12.81 390.39 1.00 785.27 677.00 0.98 3067.63 5.12 136.14 6.07 14.88 26/17 625.21 660.40 1014.35 2.22 9.02 615.55 45.79 26.25 54.75 7.75 3.79 698.70 460.34 501.48 400.25 1.18 1520.35 6.92 605.03 574.

21 61. with an unwavering focus.36 59/10 575.22 34/15 1201.33 6.96 358.08 14.52 5. This division focuses on giving the best therapeutic care in the critical care segment.20 38.94 0.55 2.00 20/11 111/26 Maxter As the face of Lupin in the critical care segment and AntiInfectives.50 4. It reaches out to interventionists and super-specialty doctors and has also ventured into the field of wound management.65 74.18 192.35 -0.90 39/19 45/14 10. The inception of Maxter has empowered Lupin to tap unexplored opportunities in chosen therapeutic area.58 5.35 301.00 310.47 315.00 322. Key Products :Maxter .34 4.01 508.50 31.Lincoln Pharma Celestial Biolabs Rubra Medicaments Syncom Formulations Alpa Lab Elder 1140. Maxter Division emulates the Company’s objective of ‘saving more lives’.68 -1. As a spin-off from Endeavour.64 26.55 352. the division was launched in 2006-07.92 0.51 32.85 4.

Product Merotrol Tazar Ceff Cetil Cefantral Product Rank in the Therapeutic segment relevant segment Meropenem Piperacillin Tazobactam Cephalexin Solids Cefuroxime Solids + Oral Oral 1 1 3 5 9 CefotaximeInjectible s PRODUCTS OF LUPIN PHARMA .

500 MG Each tablet contains RIFAMPICIN .300 MG + TUBERCULOSTATIC ETHAMBUTOL .400 MG Each tablet contains RIFAMPICIN .300 MG+ ETHAMBUTOL .150 MG + ISONIAZID .267 MG + PYRAZINAMIDE .450 MG + ISONIAZID .75 MG + ETHAMBUTOL -275 MG Each tablet contains RIFAMPICIN .450 MG + ISONIAZID .800 MG Therapy Segment TUBERCULOSTATIC AKT3 TUBERCULOSTATIC AKT4 Each Kit contains RIFAMPICIN .150 MG + ISONIAZID -75 MG Each tablet contains RIFAMPICIN .60 MG + ISONIAZID -30 MG + PYRAZINAMIDE -150 MG Each tablet contains RIFAMPICIN .150 MG + ISONIAZID .800 MG + PYRAZINAMIDE .300 MG Each Kit contains RIFAMPICIN .450 MG+ ISONIAZID .275 MG + PYRAZINAMIDE .60 MG + AKT FD AKURIT4 TUBERCULOSTATIC AKURIT3 TUBERCULOSTATIC AKURIT TUBERCULOSTATIC AKURIT Z KID TUBERCULOSTATIC AKURIT KID TUBERCULOSTATIC .75 MG +ETHAMBUTOL .1500 MG Each tablet contains RIFAMPICIN .150 MG+ISONIAZID -100 MG + TUBERCULOSTATIC ETHAMBUTOL .LupinPharma Brand Name AKT 2 Molecule Each Kit contains RIFAMPICIN .

MindVision .

Brand Name Stalopam Molecule Escitalopram 5mg Escitalopram 10mg Escitalopram 20mg Therapy Segment Antidepressant Antidepressant Antidepressant Antidepressant Nootropic Nootropic Nootropic Stalopam Plus Citistar Escitalopram 10mg + Clonazepam 0.5mg Citicoline 500mg Citicoline (250mg/ml) Citicoline 500mg (250mg/ml) Citicoline 1000 mg Sustained Release tablets Nootropic Epilive Levetiracetam 250mg Tablets Levetiracetam 500mg Tablets Levetiracetam 750mg Tablets Antiepileptics Antiepileptics Antiepileptics Antiepileptics Antiepileptics Antiepileptics Antiepileptics Antiepileptics Antiepileptics Antiepileptics Antiepileptics Agent for neurpathic pain Agent for neurpathic pain Agent for Neuropathic Pain Lovax Oxcarbazepine 150mg Oxcarbazepine 300mg Oxcarbazepine 600mg Lovax OD Oxcarbazepine 300mg Extended Release Oxcarbazepine 600mg Extended Release Dayo OD Divalproex 250mg Divalproex 500mg Divalproex 750mg Pregadoc Pregabaline 75mg Pregabaline 150mg Pregadoc M Pregabalin 75mg + Mecobalamin 750mcg Capsules Pregabalin 150mg + Mecobalamin 750mcg Agent for Neuropathic Pain .

kindly visit www.com Brand Name TONACT 5 TONACT 10 TONACT 20 TONACT 40 TONACT 80 Molecule Atorvastatin Atorvastatin Atorvastatin Atorvastatin Atorvastatin Therapy Segment Cholesterol Reducer Cholesterol Reducer Cholesterol Reducer Cholesterol Reducer Cholesterol Reducer .epinnacleworld.Pinnacle For more details on the below given information.

5 RAMISTAR H 5 RETORLIX 5 RETORLIX 10 RETORLIX 20 RETORLIX 100 .TONACT PLUS TONACT FORTE TONACT 10MG EZ TONACT 20mg EZ TONACT TG TONACT 10 MP TRITONACT Atorvastatin + Niacin Atorvastatin + Niacin Atorvastatin +Ezetimibe Atorvastatin +Ezetimibe Atorvastatin + Fenofibrate Atorvastatin Atorvastatin + Fenofibrate + Ezetimibe Atorvastatin + Telmisartan Ramipril Ramipril Ramipril Ramipril Ramipril + Amlodipine Ramipril +Hctz Ramipril +Hctz Torsemide Torsemide Torsemide Torsemide Cholesterol Reducer Cholesterol Reducer Cholesterol Reducer Cholesterol Reducer Cholesterol Reducer Cholesterol Reducer Cholesterol Reducer Cholesterol Reducer + AntiHypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Diuretic Diuretic Diuretic Diuretic TONACT-TM RAMISTAR 1.5MG RAMISTAR 5MG RAMISTAR 10MG RAMISTAR A 2.5 RAMISTAR H 2.25 RAMISTAR 2.

RETORLIX injection RETORLIX SP VALENT 40 VALENT 80mg VALENT H VALENT 160 VALENT R PINOM 10 PINOM 20 PINOM 40 MG PINOM H PINOM A 20 MG CLOPITAB 75mg CLOPITAB 150 CLOPITAB A 75 CLOPITAB A 150 CILODOC 50 CILODOC 100 Torsemide Torsemide + Spironolactone Valsartan Valsartan Valsartan + Hctz Valsartan Valsartan +Ramipril Olmesartan Olmesartan Olmesartan Olmesartan + Hctz Olmesartan + Amlodipine Clopidogrel Clopidogrel Clopidogrel + Aspirin Clopidogrel + Aspirin Cilostazol Cilostazol Diuretic Diuretic Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Antiplatelet Antiplatelet Antiplatelet Antiplatelet Antiplatelet Antiplatelet .

5/125 mg HARTY Abciximabinj Enoxaparin Enoxaparin Enoxaparin Eplerenone IsosordibeMononitrate IsosordibeMononitrate IsosordibeMononitrate Ivabradine Ivabradine Dobutamine Amlodipine Antiplatelet Anticoagulant Anticoagulant Anticoagulant Diuretic Antianginal Antianginal Antianginal Antianginal Antianginal Positive Ionotropes Anti-Hypertensive Bosentan Resveratrol + Grape seed extract Pulmonary Anti-Hypertensive Nutritional Supplement .FAXIMAB 10MG/5 ML VIAL LUPENOX 20MG LUPENOX 40MG LUPENOX 60MG PLANEP ISONORM 10 ISONORM 20 ISONORM 30 SR IVABRAD 5MG IVABRAD 7.5MG DOFUSE Injection LUPIDIP 2.5/5/10 mg LUPIBOSE 62.

Pinnacle CVN (CARDIOVASCULAR NEPHROLOGY) Brand Name ATENOVA 25 MG ATENOVA 50 MG ATENOVA 100 MG EZEDOC FRUSELAC FRUSELAC DS ISONORM 10 ISONORM 20 ISONORM 30 SR LIPRIL 2.5mg LIPRIL 5mg LIPRIL 10mg LIPRIL AM LIPRIL H Molecule Atenolol Atenolol Atenolol Ezetimibe Frusemide + Spironolactone Frusemide + Spironolactone Therapy Segment Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Cholesterol Reducer Diuretic Diuretic IsosordibeMonon Anti-Anginal itrate IsosordibeMonon Anti-Anginal itrate IsosordibeMonon Anti-Anginal itrate Lisinopril Lisinopril Lisinopril Lisinopril + Amlodipine Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Lisinorpil + Hydrochlorothiazi Anti-Hypertensive de .

5mg NEBISTAR 5mg NEBISTAR SA NEBISTAR H Nebivolol Nebivolol Nebivilol + samlodipine Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Nebivilol + Hydrochlorothiazi Anti-Hypertensive de Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive STARPRESS XL Metoprolol 100 STARPRESS XL Metoprolol 25 STARPRESS XL Metoprolol 50 STARPRESS H 25 XL STARPRESS H 50 XL STARPRESS AM XL 30 STARPRESS AM XL STARPRESS MN XL 30 STARPRESS MN XL 60 STARPRESS R XL 25 Metoprolol + Hydrochlorothiazi Anti-Hypertensive de Metoprolol + Hydrochlorothiazi Anti-Hypertensive de Metoprolol + Amlodipine Metoprolol + Amlodipine Anti-Hypertensive Anti-Hypertensive Metolprolol + Isosorbidemonon Anti-Hypertensive+Anti-Anginal itrate Metolprolol + Isosorbidemonon Anti-Hypertensive+Anti-Anginal itrate Metoprolol + Ramipril Anti-Hypertensive .NEBISTAR 2.

5 L LUPIFLO 15 L SENACEPT Metoprolol + Ramipril Ranolazine Rosuvastatin Rosuvastatin Rosuvastatin Eptifibatide Eptifibatide Tirofiban Recombinant Streptokinase Recombinant Streptokinase Cinacalcet HCL Anti-Hypertensive Anti-Anginal Cholesterol Reducer Cholesterol Reducer Cholesterol Reducer Antiplatelet Antiplatelet Antiplatelet Fibrinolytic Fibrinolytic Calcimimetic Endeavour .STARPRESS R XL 50 RANCAD NOVASTAT 5MG NOVASTAT 10MG NOVASTAT 20MG FLETA BOLUS INJ FLETA INFUSION TIROFUSE LUPIFLO 7.

5MG DEXTROMETHORPHAN + CETRIZINE + PSEUDOEPHEDRINE + MENTHOL CEFPODOXIME Therapy Segment ANTI-OSTEOPOROSIS CALUFT-G CEFAXONE 100 0 Mg CEFAXONE 125 Mg CEFAXONE 250 Mg CEFAXONE 500 Mg CEFFOREN CO-Q-DENT CO-Q-DENT CZ-3 COLD CZ-3 SYRUP CZ-3 TABLET CZ-COLD CALCIUM PREPARATION ANTI INFECTIVE INJECTABLE ANTI INFECTIVE INJECTABLE ANTI INFECTIVE INJECTABLE ANTI INFECTIVE INJECTABLE Anti-bacterial (CEPHALOSPORIN ORAL) HERBAL TOOTHPASTE HERBAL TOOTHPASTE COLD PREPARATION ANTI-HISTAMINE ANTI-HISTAMINE COLD PREPARATION CZ-EX COUGH PREPARATION CZ-TUS COUGH PREPARATION Anti-bacterial DOXCEF 100 .D3 + ZINC + MANGANESE + MAGNESIUM + COPPER CEFTRIAXONE IM/IV CEFTRIAXONE IM/IV CEFTRIAXONE IM/IV CEFTRIAXONE IM/IV CEFDITOREN CO-Q-10 CO-Q-10 PHENYLPROPANOLAMINE 25MG + CETIRIZINE 5MG + PARACETAMOL 500MG CETRIZINE CETRIZINE CETRIZINE 5MG + PSEUDOEPHEDRINE 30MG/5ML AMBROXOL 15MG + RSALBUTAMOL 1MG + GUAIPHENESIN 50 MG + MENTHOL 0.Brand Name CALUFT CAPS Molecule CALCIUM CARBONATE + CALCITRIOL + ZINC + MAGNESIUM + BORON CALCIUM CITRATE MALEATE + VIT.

Lupin Diabetes Care .

5 mg Lisinopril 5 mg Lisinopril 10 mg Lisinopril 5 mg + Amlodipine 5 mg Lisinopril 5 mg + Diabetes Management Diabetes Management Diabetes Management Diabetes Management Diabetes Management Diabetes Management Diabetes Management Diabetes Management Diabetes Management Diabetes Management Diabetic Hypertension Diabetic Hypertension Diabetic Hypertension Diabetic Hypertension .Brand Name Gluconorm SR Gluconorm SR 1g Gluconorm G1 Gluconorm G2 Gluconorm P15 Gluconorm P30 Molecule Metformin 500 mg extended release Metformin 1 gm extended release Metformin 500 mg ER + Glimepiride 1 mg Metformin 500 mg ER + Glimepiride 2 mg Metformin 500 mg ER + Pioglitazone 15 mg Metformin 500 mg ER + Pioglitazone 30mg Therapy segment Diabetes Management Diabetes Management Diabetes Management Diabetes Management Diabetes Management Diabetes Management Metformin 500 mg ER + Gluconorm PGPioglitazone 15 mg + 1 Glimepiride 1 mg Metformin 500 mg ER + Gluconorm PGPioglitazone 15 mg + 2 Glimepiride 2 mg Gluconorm G1 Forte Gluconorm G21 Forte Glutide CR 30MG Glutide CR 60MG Glador 1 Glador 2 Glador 3 Glador 4 Lipril 2.5 Lipril 5 Lipril 10 Lipril AM Metformin 1 gm ER + Glimepiride 1mg Metformin 1 gm ER + Glimepiride 2 mg Gliclazide Controlled Release 30 mg Gliclazide Controlled Release 60 mg Glimepiride 1 mg Glimepiride 2 mg Glimepiride 3 mg Glimepiride 4 mg Lisinopril 2.

These audited results were taken on record by the Board of Directors at a meeting held in Mumbai today. 37759 million from Rs. Lupin Limited.5% to Rs. Mumbai.2% at Rs.MARKET SHARE OF LUPIN PHRMA Lupin Q4 & FY 2008-09 Results Consistent Performance & Solid Growth Q4 2008-09 Consolidated Net Profits up 64. India Leading transnational pharmaceutical major. 2009. 27064 million • last year . Key Highlights . reported an outstanding performance for the fourth quarter and financial year ended March 31st.Consolidated FY 08-09 • Net sales grew at 39. 1574 million May 13. 2009.

6%% to Rs.S. said. 24701 mn Advanced markets sales (including Japan and ANZ) increased to 92% over last year and contributed 50% of the Net Sales for the year as against 36% in the previous year. 959 million in Q4 FY 07-08 Commenting on Lupin’s performance. 3338 mn in previous year (excluding IP income) EBITDA margin increased to 19. Four Major Acquisitions across Germany.3 COS. 15 DMFs. 10.2% to Rs.14310 million including API One of the fastest growing generic players in the US by prescriptions and the 9th largest in terms of total prescription base A basket of 22 products in the US with 8 market leaders Domestic Formulations Business grew at 24. Kamal K Sharma. Dr.575 million. Advanced Markets sales to US and EU grew at 70% to Rs.• • • • • • • • • • • • Net profit grew at 50. Lupin’s Japanese subsidiary. South Africa and the Philippines Dividend Announcement of 125 % Key Highlights Q4 FY 08-09 • Net sales for Q4 FY 08-09 grew at 39% to Rs. Kyowa contributed 12% of the overall revenues . • Advanced markets sales (U.6 EDMFs.2% at Rs. Australia.10434 million.Rs. 18 MAAs. 4424 million 28 ANDAs.7% Exports up by 63. Managing Director. “Lupin’s stellar performance reflects the strong business philosophy .2% to Rs. 5015 million compared to Rs. EU & Japan) increased to 86 % at Rs 5681 million over Q4 FY 07-08 • Net profit for Q4 FY 08-09 grew at 64. Lupin Limited. & 1 AU DMF were filed during FY 08-09.1574 million compared to Rs.

the company’s US subsidiary. 12563 million reflecting a growth of 74. Lupin’s Generic and Branded business recorded exponential growth during the financial year. The brand business contributed 27% to .guiding us.” Financials: Advanced markets – US & Europe Lupin continued its growth momentum in the US and Europe a healthy contribution of 36% to our total revenues at Rs. More importantly. and we are now strategically poised to not only address market needs but also maintain momentum and direction.. reported a stellar performance recording sales of Rs. 7205 million in FY 07-08.4% as compared to Rs. Lupin has had a very strong year driven by growth and consistent performance across all business segments and markets: a strong business performance in the US. Lupin’s acquisitions have not only consolidated our existing presence in these markets but also leaves us strategically poised to further strengthening our position in the global generics and branded generics market. It has indeed been a year of many achievements and robust growth. Inc. (Formulations) USA: Lupin Pharmaceuticals Inc. for marketing and promoting AeroChamber Plus® thereby extending Lupin’s presence in the respiratory segment and our franchise with Pediatricians which would also additionally open up new offices for Suprax. solid domestic growth & increased activity in all key markets. LPI forged a Strategic Alliance with Forest Laboratories. 13634 million. FY 08-09 saw Lupin increasing its product portfolio in the branded generics segment through the launch of AeroChamber Plus®.

out of which 8 are market leaders. Keppra tablets had annual sales of approximately $ 1.2 billion (USD) for the twelve months ended September 2008. or earlier in certain circumstances. Cefadroxil suspension and caps &Levetiracetam tabs. We are in the top 3 market positions by market share in 17 of these products (IMS Jan 09). ScheringPlough’s Clarinex® tablets had U. Lupin Ltd. 2012. according to IMS Health. Lupin’sLevetiracetam tablets are the AB-rated generic equivalent of UCB Pharmaceuticals’ Keppra® tablets. The Company now has a total of 22 products in the market. Food and Drug Administration (USFDA). As per the terms of the settlement. the generic version of Schering-Plough’s "Clarinex"® tablets. indicated as adjunctive therapy in the treatment of certain types of seizures associated with epilepsy.S. the company demonstrated its capabilities on the Intellectual Property management front by successfully litigating and settling all ongoing HatchWaxman litigation relating to Desloratadine tablets. 750 mg and 1000 mg from the U. Commercial shipments of the product have commenced. During the year. Divalproex DR tabs. and free to commercially launch its generic Desloratadine product. Lupin today is one of the fastest growing generic players in the US based on growth in prescriptions and the 9th largest in terms of total prescription base. on July 1. sales of $329 million for the year 2007-MAT June 2008. will be licensed under the relevant Desloratadine patents. LPI was also recognized by Wal-Mart and awarded its prestigious “Supplier Award of Excellence” for the 2nd Quarter 2008 – which is an acknowledgement of the inroads we have made into the US markets. 500mg. based on IMS Health .the overall business at USD 74 mn The company further expanded and consolidated on its generic product portfolio with the launches of Ramipril caps.S. Lupin also received the final approval for the Company’s Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets 250mg.

the Company’s subsidiary in Japan posted robust net sales of Rs. pursuant to § 130a SGB V. Hormosan has been offered to supply Setraline in all 5 regions of Germany covering all AOK-insured persons. Hormosan has a strong brand identity in the German generics market through its strong patient compliance message. a German generics company specialized in the supply of pharmaceutical products for the Central Nervous System (CNS). Europe: Lupin further strengthened its presence in the European Union by completeing its acquisition of HormosanPharma GmbH (Hormosan). continue to exhibit market leadership in unit terms. We also recorded our first strategic win in the German market through Hormosan in the next two quarters – having received information on the results of the AllgemeineOrtskrankenkassen (AOK) Tender. essential for patients within the CNS sector. AAMLA Japan: Kyowa. Lupin also made strategic inroads into the French market by launching CefpodoximeProxetil suspension in Q3. 4424 mn contributing 12% of Lupin’s Revenues having grown at over 21 % YoY Our products like Amlodipine “Amel” continues to maintain majority market share and Risperidone “Amel”. Pharma Dynamics is one of the . CefpodoximeProxetil has over 60 % market share in France.sales data. South Africa Lupin clocked in revenues of Rs 919 million after having acquired an equity stake in Pharma Dynamics (PD) in South Africa in September 08. which was launched last year.

Research and Development Research & Development has always been a strategic and . (MC) in Phillipines. taking the cumulative MAA filings to 24 till date of which 18 have been approved. CNS. PD is ranked number 6 amongst generic companies in South Africa. ANZ The Company continued its focus on this important market with aggressive filings in Australia. Diabetes.487 million registering a growth of 24. Asthma and Gastro therapy Segments. Inc. The South African Generics Market is currently valued at close to 800 Million USD and growing rapidly Phillipines In March 2009 the Company acquired a majority stake in MulticarePharmaceuticals Phillipines.fastest growing generic companies in South Africa growing at around 30 % for FY 08-09 with a clear leadership in the cardiovascular segment. The divisions catering to branded segments continued to outpace the industry growing over 27%. 8.6% over the previous year. In the current financial year. Emerging Markets India Domestic Formulations forms a very important part of Lupin’s overall growth. MC is a premium branded generics company with a strong position in women’s health and child care segment. Lupin has maintained its leadership in Anti-TB segment and has secured a double digit market share in the anti-asthma market riding high on the strengths of its offering in this segment. it contributed about 28% of the net sales at Rs 10.575 million as against Rs. This growth was driven by the good performance in the CVS.

COMPANY MANUFACTURING/R&D . 750 mg and 1000 mg from the U. 10 each.50 per equity share of the face value of Rs. Dividend-In view of excellent performance. 11 DMFs. The cumulative ANDA filings stood at 90 with 34 approvals granted by the USFDA.key focus area for Lupin and this year – 2008-09 was no exception with 6% of the sales earmarked for R&D and related spends. 2008 for a routine GMP inspection. Lupin also received the final approval for the Company’s Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets 250mg. 15 MAAs and two EDMFs during the year. the Board of Directors recommended a dividend of 125 % i.S. All products maintain their approved status. Lupin manufacturing will not be disrupted and it will continue to provide quality products to customers without interruption. 12. Other The USFDA issued a warning letter for the Cephalosporin facility of the Mandideep plant. Lupin has formulated a strategy to address and resolve the USFDA and is confident of being able to satisfy the USFDA’s observations expeditiously. As a result Lupin had received 15 procedural observations.eRs. Lupin responded to the observations in December and provided corrective actions for each of the responses. The year 2008-09 was a landmark year with Lupin filing 28 Abbreviated New Drug Application (ANDA) with the USFDA. Food and Drug Administration (USFDA) during the quarter. The warning letter was issued to provide Lupin with an opportunity to submit additional documentation and explanation to a few selected observations where the FDA felt that the initial responses were inadequate and could be strengthened by further evidence of compliance with enhanced documentation practices. 500mg. The facility was inspected in November.

• Licensing and acquisitions. Our scientists apply know how and expertise to develop NCE’s or to solve difficult formulation challenges. Our company strives to bring important new products to market each year. We strive for continued growth and are avidly interested in learning about prospective opportunities in the specialty pharmaceutical market.Business Development Top of Form Lupin was founded to meet the very basic need for effective treatment of tuberculosis. We are also open to collaborating to develop innovative products formulated with Lupin’s drug delivery and taste masking technology.com NEW Products . Our API business unit is seeking partners for Lupin developed API's. Please contact us regarding business or product collaboration opportunities Phone: 410-576-2000 Facsimile: 410-576-2221 Email: admin@lupinusa. Lupin is also seeking to be the partner of choice for product development. We expect our products to come from: • In-house product development. • Marketing alliances. Our success is tied to continually meeting the need for basic products to promote human health.

Paragraph IV’s. Six of Lupin's 14 ANDA approvals were the first granted by the US FDA. from process development of the API to the submission of dossiers for finished dosages. allow us to file and manufacture a wide range of finished products for the US market. US FDA approved manufacturing sites and the new tablet and capsule facility in Goa. Lupin Pharmaceuticals. Since then we have received more than a dozen FDA approvals. We are vertically integrated. Our integrated manufacturing capability provides a portfolio of the highest quality generic products. Newsroom Lupin receives FDA approval for Imipramine Pamoate Apr 16. Inc. Our oral and injectable cephalosporin facilities. Cardiovascular. Expanding the product portfolio. Inc. entered the U. is geared to file 15 or more ANDA’s per year in some of the following areas: Oral and injectable cephalosporins. reinforcing our ability to submit high quality dossiers and gain on time approvals. This provides control over the supply chain and the ability to offer quality products at the right time and at competitive prices. 2010 .S. Controlled release ANDA’s. generic pharmaceutical market in 2003 with the ANDA approval for cefuroxime axetil.Generics Lupin Pharmaceuticals.

2010 Lupin receives FDA approval for Amlodipine/Benazepril Feb 08. 2009 Lupin Receives “Supplier Award of Excellence” from Wal-Mart View Sept 17.Capsules View Lupin receives FDA tentative approval for Eszopiclone tablets View Mar 20. 2010 Lupin receives FDA tentative approval for MemantineHCl tablets View Jan 19. 2008 . 2010 capsules View Lupin receives FDA approval for Perindopril Erbumine Tablets View Jan 28. 2010 Lupin is granted USFDA approval for Levetiracetam Tablets View Jan 16.

2008 Lupin launches Ramipril capsules View June 10. 2008 Lupin receives USFDA approval for Escitalopram Oxalate Tablets View June 16. View June 26. 2007 . 2008 View Lupin Receives “Best New Manufacturer of the Year” Award from AmerisourceBergen View July 30.S. 2008 Lupin Enters Into Marketing Alliance with ASCEND Therapeutics for SUPRAX® 400 mg Tablets in the U. 2007 Lupin receives final approval for Amlodipine Tablets July 12. 2008 Delayed-Release Tablets View Lupin appoints New NCE Research Head.Lupin receives USFDA approval for Divalproex Sodium July 29. View June 23. 2008 Lupin receives USFDA approval for Topiramate Tablets May 29.

View May 8. 2007 View Lupin Receives US FDA Approval for ZiprasidoneHCl Capsules View May 22. 2007 Lupin Receives US FDA Approval for Novel Formulation April 12. Launches Entire Product Family. 2007 Products . of Suprax® Suspension 2007 View Lupin Receives US FDA Approval for Sertraline. View February 7. 2007 Lupin Announces Final FDA Approval of Cefdinir for Oral Suspension. 250 mg/5 mL.View Lupin announces Final Approval of Trandolapril Tablets June 13.

Lupin has created a dedicated national sales force to call upon pediatricians. API . is very pleased to offer Suprax®.. We are committed to identifying.Specialty A commitment To Caring For Kids Lupin Pharmaceuticals.. is committed to developing a branded pharmaceutical presence for pediatric practice in the US market. Inc. We plan to expand our family of pediatric products to help meet needs of children. Suprax® is now available in tablets and suspension formulations. has an exclusive license in the United States to use the Suprax® trademark. Lupin Pharmaceuticals. Our focus is on in-house product development with our proprietary oral controlled release and taste masking platforms. developing and marketing prescription drugs for children of all ages. is also open to marketing alliances. and to licensing/acquisitions. Inc. an important anti-infective product in pediatric and other physician practices within the United States. Inc. Lupin Pharmaceuticals. Lupin Pharmaceuticals. Inc.

Lupin is recognized as a leading manufacturer of cephalosporin API’s. synthetic process development and fermentation skills coupled with its intellectual property strengths. with FDA approval to manufacture complex oral and injectable cephalosporins. Lupin’s capabilities in sterile processing. Diabetology. Asthma and NSAIDs(Non-steroidal anti- . puts the company in a very strong position to offer a diverse portfolio of niche API’s to its customers. The Company is the world’s largest manufacturer of Tuberculosis drugs. Business Overview Headquartered in Mumbai. SHARE IN MARKET ANNUL Lupin Limited (NSE:EQLUPIN) Lupin Limited is amongst the top six pharmaceutical companies in India in terms of revenue. India Lupin Limited is a transnational pharmaceutical company producing generic and branded formulations and Active Pharmaceutical Ingredients(APIs)[1]The Company has secured global leadership position in Anti-TB and Cephalosporins and has a significant presence in the areas of Cardiovasculars (prils and statins). Lupin is fast gaining share in the cardiovascular segment manufacturing a wide range of ACE-inhibitors and cholesterol reducing agents.

Inst.62% Foreign Promoters 0.2% at Rs. [1] Business and Financial Metrics Lupin Limited's share holding pattern [4] Entity Percentage Indian Promoters 50.01% FII's 11.Net sales growth for Q4 FY 08-09 was 39% at Rs.inflammatory drugs)[1] Net profit for Q4 FY 08-09 grew at 64.76%Private Corporate Bodies1.13% Business Segments Formulations Active Pharamceutical Ingredients and Intermediates ROCE is comparable to the best in the segment at 33%[6] \ .48%NRI's/OCB's/Foreign Others2.21%Banks Fin. and Insurance09.90%Others0.15% General Public9. 10434 million. 1574 million compared to Rs 959 million in Q4 FY 07-08.

.

42 2.87 2.22 Market Share on the basis of Retail Sales Due to high level of fragmentation none of the Pharma Companies had more than 6% of the total market on the basis of the total retail sales.975.[15] .661.35 1.66 4. [12]In India it the biggest drug maker by sales[13] Comparison with the competitors: Financial metrics FY2008 Yr Ende d Mar '08 Mar '08 Mar '08 Market Capitalization in Rs Cr Sales Turnove r in Rs Cr Name Net Profit in Rs Cr Lupin 6.40 475.in India and a presence in more than 100 countries.473.293.57 9.662.014.95 701.62 443.38 Sun Pharma 26.64 576.427.992.762.428.41 1.947.04 Cipla 17.53 3.43 GlaxoSmith Dec Kline '07 DrReddys Labs Mar '08 9.

15 MAAs and two EDMFs during the year. 500mg. The facility was inspected in November. Food and Drug Administration (USFDA) during the quarter. 2008 for a routine GMP inspection.S. The year 2008-09 was a landmark year with Lupin filing 28 Abbreviated New Drug Application (ANDA) with the USFDA. Lupin has maintained its leadership in Anti-TB segment and has secured a double digit market share in the antiasthma market riding high on the strengths of its offering in this segment. As a result Lupin had received 15 procedural observations. Lupin also received the final approval for the Company¶s Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets 250mg. The divisions catering to branded segments continued to outpace the industry growing over 27%.Diabetes. . 750 mg and 1000 mg from the U. The warning letter was issued to provide Lupin with an opportunity to submit additional documentation and explanation to a few selected observations where the FDA felt that the initial responses were inadequate and could be strengthened by further evidence of compliance with enhanced documentation practices. CNS. Asthma and Gastro therapy Segments. The cumulative ANDA filings stood at 90 with 34 approvals granted by the USFDA. 11 DMFs. Research and Development Research & Development has always been a strategic and key focus area for Lupin and this year ± 2008-09 was no exception with 6% of the sales earmarked for R&D and related spends. Other The USFDA issued a warning letter for the Cephalosporin facility of the Mandideep plant. Lupin responded to the observations in December and provided corrective actions for each of the responses.

Lupin has formulated a strategy to address and resolve the USFDA and is confident of being able to satisfy the USFDA¶s observations expeditiously. Our company strives to bring important new products to market each year. Our success is tied to continually meeting the need for basic products to promote human health. Marketing alliances. Lupin manufacturing will not be disrupted and it will continue to provide quality products to customers without interruption. We strive for continued growth and are avidly interested in learning about prospective opportunities in the specialty pharmaceutical market. Our API business unit is seeking partners for Lupin developed API's. the Board of Directors recommended a dividend of 125 % i. Licensing and acquisitions. Dividend-In view of excellent performance. 12.50 per equity share of the face value of Rs. Please contact us regarding business or product collaboration opportunities . COMPANY MANUFACTURING/R&D Business Development Lupin was founded to meet the very basic need for effective treatment of tuberculosis.eRs. Our scientists apply know how and expertise to develop NCE¶s or to solve difficult formulation challenges.All products maintain their approved status. Lupin is also seeking to be the partner of choice for product development. 10 each. We expect our products to come from: y y y In-house product development. We are also open to collaborating to develop innovative products formulated with Lupin¶s drug delivery and taste masking technology.

Our integrated manufacturing capability provides a portfolio of the highest quality generic products.S. Six of Lupin's 14 ANDA approvals were the first granted by the US FDA. reinforcing our ability to submit high quality dossiers and gain on time approvals. generic pharmaceutical market in 2003 with the ANDA approval for cefuroxime axetil. This provides control over the supply chain and the ability to offer quality products at the right time and at competitive prices. entered the U.com NEW Products Generics Lupin Pharmaceuticals.Phone: 410-576-2000 Facsimile: 410-576-2221 Email: admin@lupinusa. Inc. Since then we have received more than a dozen FDA approvals. Expanding the product portfolio. We are vertically integrated. Lupin . from process development of the API to the submission of dossiers for finished dosages.

2010 Lupin receives FDA approval for Amlodipine/Benazepril Feb 08. is geared to file 15 or more ANDA¶s per year in some of the following areas: Oral and injectable cephalosporins. Newsroom Lupin receives FDA approval for Imipramine Pamoate Capsules View Apr 16. Paragraph IV¶s. 2010 Lupin receives FDA tentative approval for Eszopiclone tablets View Mar 20. Cardiovascular. Controlled release ANDA¶s. allow us to file and manufacture a wide range of finished products for the US market. 2010 capsules View . US FDA approved manufacturing sites and the new tablet and capsule facility in Goa. Inc. Our oral and injectable cephalosporin facilities.Pharmaceuticals.

2008 Lupin receives USFDA approval for Divalproex Sodium Delayed-Release Tablets View July 29. . 2008 Lupin Enters Into Marketing Alliance with ASCEND June 23. 2010 tablets View Lupin is granted USFDA approval for Levetiracetam Tablets View Jan 16.Lupin receives FDA approval for Perindopril Erbumine Tablets View Jan 28. 2009 Lupin Receives ³Supplier Award of Excellence´ from Wal-Mart View Sept 17. 2010 Lupin receives FDA tentative approval for MemantineHCl Jan 19. View June 26. 2008 Lupin appoints New NCE Research Head.

2007 Lupin announces Final Approval of Trandolapril Tablets June 13. 2007 Lupin receives final approval for Amlodipine Tablets View July 12.S. 2008 Lupin receives USFDA approval for Topiramate Tablets May 29. View 2008 Lupin receives USFDA approval for Escitalopram Oxalate Tablets View June 16. 2008 Lupin launches Ramipril capsules View June 10.Therapeutics for SUPRAX® 400 mg Tablets in the U. 2007 View . 2008 View Lupin Receives ³Best New Manufacturer of the Year´ Award from AmerisourceBergen View July 30.

2007 Products . 2007 Lupin Announces Final FDA Approval of Cefdinir for Oral Suspension. 250 mg/5 mL. View February 7. View May 8.Lupin Receives US FDA Approval for ZiprasidoneHCl Capsules View May 22. of Suprax® Suspension 2007 View Lupin Receives US FDA Approval for Sertraline. Launches Entire Product Family. 2007 Lupin Receives US FDA Approval for Novel Formulation April 12.

Lupin Pharmaceuticals. is very pleased to offer Suprax®. We are committed to identifying. and to licensing/acquisitions. Lupin Pharmaceuticals. Our focus is on in-house product development with our proprietary oral controlled release and taste masking platforms. is also open to marketing alliances.. Inc. Lupin Pharmaceuticals. Inc. Lupin has created a dedicated national sales force to call upon pediatricians. Inc.Specialty A commitment To Caring For Kids Lupin Pharmaceuticals. Suprax® is now available in tablets and suspension formulations. is committed to developing a branded pharmaceutical presence for pediatric practice in the US market. Inc.. an important anti-infective product in pediatric and other physician practices within the United States. API . developing and marketing prescription drugs for children of all ages. has an exclusive license in the United States to use the Suprax® trademark. We plan to expand our family of pediatric products to help meet needs of children.

Lupin¶s capabilities in sterile processing. Diabetology. India Lupin Limited is a transnational pharmaceutical company producing generic and branded formulations and Active Pharmaceutical Ingredients(APIs)[1]The Company has secured global leadership position in Anti-TB and Cephalosporins and has a significant presence in the areas of Cardiovasculars (prils and statins). synthetic process development and fermentation skills coupled with its intellectual property strengths. Lupin is fast gaining share in the cardiovascular segment manufacturing a wide range of ACE-inhibitors and cholesterol reducing agents. SHARE IN MARKET ANNUL Lupin Limited (NSE:EQLUPIN) Lupin Limited is amongst the top six pharmaceutical companies in India in terms of revenue. with FDA approval to manufacture complex oral and injectable cephalosporins. Asthma and NSAIDs(Non-steroidal anti-inflammatory drugs)[1] . Business Overview Headquartered in Mumbai. puts the company in a very strong position to offer a diverse portfolio of niche API¶s to its customers. The Company is the world¶s largest manufacturer of Tuberculosis drugs.Lupin is recognized as a leading manufacturer of cephalosporin API¶s.

10434 million. 1574 million compared to Rs 959 million in Q4 FY 07-08.48%NRI's/OCB's/Foreign Others2.76%Private Corporate Bodies1.Net sales growth for Q4 FY 08-09 was 39% at Rs. and Insurance09.2% at Rs.Net profit for Q4 FY 08-09 grew at 64. Inst.62% Foreign Promoters 0.21%Banks Fin.01% FII's 11.15% General Public9.90%Others0.13% Business Segments Formulations Active Pharamceutical Ingredients and Intermediates ROCE is comparable to the best in the segment at 33%[6] \ .[1] Business and Financial Metrics Lupin Limited's share holding pattern [4] Entity Percentage Indian Promoters 50.

Sun Pharmaceutical Industries Inc (subsidiary)[8]  [9] Cipla .Competition The pharmaceutical industry is characterized by rapid advances in scientific knowledge and ability to discover new drugs.It has brands in 30 markets worldwide and also has a generic presence in the U. dermatologicals and pain management drugs [11] [10] Its main portfolios consists of anti-  Dr. and veterinary products to some 180 countries around the world. 1500 crore is one of the market leaders(market share) in India with a share of 6. prescription drugs. over-the-counter products.It is one of the oldest pharma companies in India and with a turnover of Rs.[8].The industry is therefore led by large manufacturers and marketers of drugs investing heavily in research & development. with Caraco Pharm Labs.Cipla is a leader in the domestic retail pharmaceutical market. Reddy's Laboratories . gastroenterology. It also exports raw materials.Some of the main competitors of Lupin are:  Sun PharamceuticalsIndustires . having clinical testing.It is a global pharmaceutical company with it's headquarters in India and a presence in more than 100 countries. intermediates. cardiology. neurology.[12]In India it the biggest drug maker by sales[13] Comparison with the competitors: .It is No. 1 in India in speciality therapy areas like psychiatry. marketing and distributing capabilities[7].2 per cent infectives.S.[9]  GlaxoSmithKline . diabetology and respiratory.

57 475.04 701.95 1.35 4.40 443.473.662.87 Mar '08 17.53 Market Share on the basis of Retail Sales Due to high level of fragmentation none of the Pharma Companies had more than 6% of the total market on the basis of the total retail sales.38 1.62 2.947.975.427.42 Mar '08 26.Financial metrics FY2008 Name Lupin Sun Pharma Cipla Yr Ended Market Capitalization in Rs Cr Sales Turnover in Rs Cr Net Profit in Rs Cr Mar '08 6.22 GlaxoSmithKline Dec '07 DrReddys Labs Mar '08 9.66 9.293.41 2.428.64 3.014.43 576.992.[15] .661.762.

.

KEY DEVELOPMENTS FOR LUPIN PHARMACEUTICALS. announced that it has been granted final . Inc. Lupin Pharmaceuticals. INC. Gets US FDA Nod for Anti-Depressant 04/20/2010 Lupin Pharmaceuticals. Inc.

Lupin informed Bayer Schering Pharma and Bayer HealthCare Pharmaceuticals that it had filed an ANDA to manufacture a generic Cipro (ciprofloxacin) oral solution in 250 mg/5 mL and 500 mg/5 mL strengths before patent protection ends . Lupin's Imipramine Pamoate capsules are generic equivalent of Mallinckrodt's Tofranil-PM. Inc. The product will be introduced in the market through LPI's strong network of national wholesalers and pharmacy chains post patent expiry in 2012.S. 1 mg. 2009. Inc. announced that it has received tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Eszopiclone tablets. The brand product had annual sales of approximately $761 million for the twelve months ended December 2009. Food and Drug Administration (USFDA). 125 mg and 150 mg. indicated for the treatment of insomnia. in a patent dispute over the oral solution of the antibiotic Cipro. The drug had an annual sales of about $39 million for the year ended December. Lupin Receives FDA Tentative Approval for Eszopiclone Tablets 03/22/2010 Lupin Pharmaceuticals. 100 mg. The company's Eszopiclone tablets are the ABrated generic equivalent of Sepracor's LUNESTAR tablets. based on IMS Health sales data. The drug is recommended for relieving depression symptoms. Bayer AG Sues Lupin Pharmaceuticals in Patent Dispute over Oral Solution of the Antibiotic Cipro 03/9/2010 Bayer AG is suing Lupin Pharmaceuticals.approval from the Food and Drug Administration (FDA) for the capsules in strengths of 75 mg. 2 mg and 3 mg from the U.

Sign up to vote on this title
UsefulNot useful